Study of CBL0137 with Ipilimumab and Nivolumab for Melanoma
This study is testing a new drug called CBL0137 in combination with two standard melanoma treatments, Ipilimumab and Nivolumab, for people with locally advanced or metastatic melanoma. Researchers want to see how safe this combination is and what effects it has on the body. You might be able to join if you have stage III or IV melanoma that can be biopsied. The study will look at safety and how well people tolerate the treatment over 28 days. The study is currently unclear on its recruitment status and plans to enroll 12 participants.
- Study design
- This is a Phase I, open-label study, meaning you and your doctors will know which treatments you are receiving. It is a dose-escalation study, meaning participants will receive different doses of CBL0137.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The initial assessment of safety and tolerability will be measured at 28 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anthony Olszanski, MD · PRINCIPAL_INVESTIGATOR · Fox Chase Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Initial assessment of safety and tolerability of the combination of CBL0137 with Nivolumab and Ipilimumab.28 days
The primary endpoint will be safety/tolerability of the combination of CBL0137 with ipilimumab and nivolumab. Patients will be treated as part of assigned dose level in planned 3+ 3 design with 3 possible dose levels and assessed for Dose limiting toxicities ( DLTs)